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AbstrAct
Introduction Despite therapeutic advances, many 
individuals with type 1 diabetes are unable to achieve 
tight glycaemic target without increasing the risk of 
hypoglycaemia. The objective of this study is to determine 
the effectiveness of a 3-month day-and-night home 
closed-loop glucose control combined with a pump 
suspend feature, compared with sensor-augmented insulin 
pump therapy in youths and adults with suboptimally 
controlled type 1 diabetes.
Methods and analysis The study adopts an open-label, 
multi-centre, multi-national (UK and USA), randomised, 
single-period, parallel design and aims for 84 randomised 
patients. Participants are youths (6–21 years) or adults 
(>21 years) with type 1 diabetes treated with insulin 
pump therapy and suboptimal glycaemic control (glycated 
haemoglobin (HbA1c) ≥7.5% (58 mmol/mol) and ≤10% 
(86 mmol/mol)). Following a 4-week run-in period, eligible 
participants will be randomised to a 3-month use of 
automated closed-loop insulin delivery combined with 
pump suspend feature or to sensor-augmented insulin 
pump therapy. Analyses will be conducted on an intention-
to-treat basis. The primary outcome is the time spent in 
the target glucose range from 3.9 to 10.0 mmol/L based on 
continuous glucose monitoring levels during the 3-month 
free-living phase. Secondary outcomes include HbA1c at 
3 months, mean glucose, time spent below and above 
target; time with glucose levels <3.5 and <2.8 mmol/L; 
area under the curve when sensor glucose is <3.5 mmol/L, 
time with glucose levels >16.7 mmol/L, glucose variability; 
total, basal and bolus insulin dose and change in body 
weight. Participants’ and their families’ perception in terms 
of lifestyle change, daily diabetes management and fear of 
hypoglycaemia will be evaluated.
Ethics and dissemination Ethics/institutional review 
board approval has been obtained. Before screening, 
all participants/guardians will be provided with oral 
and written information about the trial. The study will 
be disseminated by peer-reviewed publications and 
conference presentations.
Trial registration number NCT02523131; Pre-results.
IntroductIon
Type 1 diabetes mellitus (T1D) is caused by 
an immune-mediated destruction of insu-
lin-producing pancreatic beta-cells resulting 
in insulin deficiency.1 It commonly presents 
in childhood, but one-fourth of cases are diag-
nosed in adults. T1D accounts for 5%–10% 
of the total diabetes cases worldwide.2 The 
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Protocol
Strengths and limitations of this study
 ► The study adopts a multi-centre, multi-national, 
randomised, parallel design
 ► The study includes youth and adult participants 
across a wide range of age groups and geographical 
locations
 ► Participants in both study arms have equal numbers 
of study visits
 ► The study excludes participants who are 
hypoglycaemia unaware, living alone and those with 
HbA1c below 7.5% and above 10%
 ► The study is open-label, and the comparator does 
not include the use of pump suspend feature
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Table 1 Primary outcome of four randomised free-living unsupervised home day-and-night closed-loop studies
Study
Duration of home 
closed loop (days) Population
Time spent in target (%)
p Value ReferenceClosed loop Control
Dan04 phase 1 7 Adolescents 72 53 <0.001 Tauschmann et al24
Dan04 phase 2 21 Adolescents 67 48 <0.001 Tauschmann et al25
AP@home02 7 Adults 75 63 0.006 Leelarathna et al23
AP@home04 phase 1 84 Adults 68 57 <0.001 Thabit et al10
AP@home04 phase 2 28 Adults 76 66 <0.001 Bally et al26
incidence of T1D is still increasing by around 3% every 
year, particularly among children.2 Around 86 000 chil-
dren develop T1D each year, and in 2015, the number 
of children with T1D exceeded half a million for the first 
time.2
Despite rapid advancements in insulin delivery and 
the on-going development of more physiological insulin 
preparations,3 achieving optimal glycaemic control 
while avoiding hypoglycaemia remains a challenge for 
many people with T1D. The emergence of continuous 
glucose monitoring (CGM) over the last decade,4 5 which 
enables users to view real-time interstitial glucose read-
ings and receive alarms for impending hypoglycaemia 
or hyperglycaemia, facilitating appropriate changes 
in insulin therapy, is a major step towards improved 
diabetes monitoring. Studies have shown the clinical 
benefit of CGM in reducing HbA1c with regular use of 
the device.6 Sensor-augmented pumps (SAPs) combine 
real-time CGM with insulin pump therapy, and studies 
have shown HbA1c reduction compared with multiple 
daily injection basal–bolus therapy.7 Automatic suspen-
sion of insulin delivery by the pump when a predefined 
threshold is reached (low glucose suspend feature) has 
been demonstrated to significantly reduce the burden of 
hypoglycaemia.8
The development of a closed-loop system that combines 
glucose monitoring with computer-based algorithm-di-
rected insulin delivery9 may provide further improvements 
in glycaemic control while reducing hypoglycaemia10 11 
and represents an emerging treatment option for people 
with T1D.12 Closed-loop differs from conventional pump 
therapy, characterised by preprogrammed basal delivery, 
through the use of a control algorithm that directs subcu-
taneous insulin delivery according to sensor glucose 
levels. People with T1D are known to have significant 
variability in daily insulin requirements,13 which may be 
addressed by closed loop.
Closed-loop studies have progressed from fully super-
vised research facility settings14 15 to remotely monitored 
transitional settings such as diabetes camp and hotel 
settings.16 17 The use of closedloop during unsupervised 
free living conditions over extended periods represents 
the ultimate testing bed within the target environment 
(table 1). The longest randomised day-and-night home 
study to date has shown benefit in glycaemic control with 
concurrent reduction of the risk of hypoglycaemia.10 On 
the basis of a recent non-randomised 3-month pivotal 
study,12 the US Food and Drug Administration (FDA) 
approved the insulin-only closed-loop system for use in 
clinical practice.18
No study thus far has combined the pump suspend 
feature8 with closed-loop insulin delivery. In previous 
closed-loop systems, preprogrammed basal insulin rates 
are delivered in the event of communication failure 
between control algorithm device and the insulin pump. 
In the present closed-loop system, in-built pump suspend 
feature is immune to such communication failures and 
will operate even if the control algorithm device is not 
in range, reducing the risk of prolonged hypoglycaemia. 
Thus, the addition of pump suspend feature to a closed-
loop system further increases user safety by discontinuing 
insulin delivery at low sensor glucose levels.
We plan to assess the efficacy, safety, utility and accept-
ability of a 3-month day-and-night home closed-loop 
glucose control combined with pump suspend feature in 
youths and adults under free-living conditions compared 
with SAP therapy.
Methods and analysIs
overview
This is an open-label, multi-centre, multi-national, 
randomised, one-period, parallel study contrasting day-and-
night automated closed-loop glucose control combined 
with pump suspend feature (threshold suspend) to therapy 
during free-living home setting (figure 1, protocol version 
5.0 dated 28 February 2017). Study participants will include 
youths and adults with suboptimally controlled T1D treated 
with insulin pump therapy. Recruited participants will be 
randomly assigned to 3 months of study intervention. The 
study will aim to randomise 84 participants stratified at 
study site, as appropiate, according to the two age groups, 
which will be based on the age of minors in the USA (equal 
proportions of youths (6–21 years) and adults (22 years 
and older)). The University of Cambridge (UK) and Jaeb 
Center (USA) will be the coordinating centres. Clinical sites 
include:
1. Addenbrooke’s Hospital, Cambridge, UK (adults and 
youths)
2. Royal Hospital for Sick Children, Edinburgh, UK 
(youths)
3. Leeds Teaching Hospital, Leeds, UK (youths)
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Figure 1 Study flow chart. CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin. 
4. Manchester Royal Infirmary, Manchester, UK (adults)
5. International Diabetes Center at Park Nicollet, 
Minneapolis, USA (adults and youths)
6. Barbara Davis Center for Childhood Diabetes, Aurora, 
USA (adults)
Qualitative interviews will be carried out by the Univer-
sity of Edinburgh, UK. Written informed consent/assent 
will be obtained from all participants and guardians, as 
appropriate, before any study-related activities.
Inclusion criteria
 ► At least 6 years or older (with equal proportion of 
youths (6–21 years) and adults (22 years and older))
 ► T1D as defined by WHO for at least 1 year or confirmed 
C peptide negative
 ► An insulin pump user for at least 3 months, with good 
knowledge of insulin self-adjustment as judged by the 
investigator
 ► Treated with one of the U-100 rapid-acting insulin 
analogues only (insulin aspart, lispro but not 
glulisine)
 ► Willing to perform regular capillary blood glucose 
monitoring, with at least four blood glucose 
measurements taken every day
 ► Screening HbA1c ≥7.5% (58.5 mmol/mol) and ≤10% 
(86 mmol/mol) based on analysis from local 
laboratory or equivalent
 ► Literate in English
 ► Willing to wear CGM
 ► Willing to wear closed-loop system at home
 ► Willing to follow study-specific instructions
 ► Willing to upload pump and CGM data at regular 
intervals
 ► Willing to restrict alcohol consumption to ≤2 units 
per day throughout the study period
 ► Female participants of child-bearing age should be 
on effective contraception and must have a negative 
urine-HCG pregnancy test at screening
 ► Living with someone who is trained to administer 
intramuscular glucagon and is able to seek emergency 
assistance
 ► Access to Wi-Fi at home.
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exclusion criteria
 ► Non-T1D including those secondary to chronic 
disease
 ► Using real-time CGM on regular basis in preceding 3 
months
 ► Any other physical or psychological disease likely to 
interfere with the normal conduct of the study and 
interpretation of the study results as judged by the 
investigator
 ► Untreated coeliac disease, adrenal insufficiency or 
hypothyroidism
 ► Current treatment with drugs known to interfere 
with glucose metabolism, for example, systemic 
corticosteroids, non-selective beta-blockers and 
monoamine oxidase inhibitors, among others
 ► Known or suspected allergy to insulin
 ► Clinically significant nephropathy (estimated 
glomerular filtration rate <45 mL/min) or on 
dialysis, neuropathy or active retinopathy (defined as 
the presence of maculopathy or proliferative changes) 
as judged by the investigator
 ► Adults: one or more episodes of severe hypoglycaemia 
as defined by American Diabetes Association19 in 
preceding 6 months; youths: one or more episodes of 
severe hypoglycaemia during the previous 6 months 
(adults and adolescents: severe hypoglycaemia is 
defined as an event requiring assistance of another 
person to actively administer carbohydrates or 
glucagon or take other corrective actions including 
episodes of hypoglycaemia severe enough to cause 
unconsciousness, seizures or attendance at hospital; 
children: severe hypoglycaemia is defined as an event 
associated with a seizure or loss of consciousness)
 ► Random C peptide >100 pmol/L with concomitant 
blood glucose >4 mmol/L (72 mg/dL)
 ► Regular use of acetaminophen
 ► Lack of reliable telephone facility for contact
 ► Total daily insulin dose ≥2 IU/kg/day
 ► Total daily insulin dose <15 IU/day
 ► Pregnancy, planned pregnancy or breast feeding
 ► Severe visual impairment
 ► Severe hearing impairment
 ► Significantly reduced hypoglycaemia awareness in 
participants aged 18 years and older defined by Gold 
score of >4
 ► Using implanted internal pace-maker
 ► Medically documented allergy towards the adhesive 
(glue) of plasters or unable to tolerate tape adhesive 
in the area of sensor placement
 ► Serious skin diseases (eg, psoriasis vulgaris, bacterial 
skin diseases) located at places of the body, which 
potentially are possible to be used for the localisation 
of glucose sensor
 ► Currently abusing alcohol, illicit drugs or prescription 
drugs
 ► Using pramlintide (symlin) or other commonly used 
hypoglycaemic agents including sulphonylureas, 
biguanides, DPP4 inhibitors, GLP-1 agonists, SGLT-2 
inhibitors at time of screening
 ► Elective surgery planned that requires general 
anaesthesia during the course of the study
 ► Shift worker with working hours between 22:00 and 
08:00
 ► Sickle cell disease or haemoglobinopathy
 ► Red blood cell transfusion or erythropoietin within 
3 months prior to the time of screening or plans to 
receive red blood cell transfusion or erythropoiesstin 
during the course of study participation
 ► Diagnosed with current eating disorder such as 
anorexia or bulimia
 ► Plans to use significant quantity of herbal preparations 
(use of over-the-counter herbal preparation for 30 
consecutive days or longer period during the study) 
or significant quantity of vitamin supplements (four 
times the recommended daily allowance used for 30 
consecutive days or longer period during the study), 
which may affect glucose metabolism and/or blood 
glucose levels during the course of their participation 
in the study.
study schedule
The study will consist of up to 11 in-clinic visits and 6 
preplanned telephone/email contacts. Overview and key 
activities of the study visits are shown in tables 2 and 3, 
with both intervention periods lasting 3 months.
study training
Following written informed consent, participants will 
be trained on the use of study insulin pump (modified 
Medtronic 640G pump, Medtronic MiniMed, Northridge, 
California, USA) and CGM sensor (Enlite 3, Medtronic). 
For minors, parents/guardians will provide written 
informed consent, and written assent will be obtained 
from minors. Training will be performed in the presence 
of parents/guardians. The study insulin pump will be 
preprogrammed using participants’ usual basal settings, 
carbohydrate-to-insulin ratio and insulin sensitivity factor. 
Competency on use of study devices with the participant 
(cosignature of guardian will be required in US partici-
pants) will be formally assessed.
run-in period
There will be a minimum 4-week run-in period. Partici-
pants will be contacted once weekly by phone or email 
for troubleshooting purposes. At the end of the run-in 
period, study devices will be downloaded to assess adher-
ence during the last 14 days (participants will be required 
to demonstrate at least 12 days’ use of CGM and use 
of at least 75% of bolus calculator for meal boluses for 
randomisation). Participants need to perform weekly 
downloads of study devices.
randomisation
Eligible subjects will be randomised using central rando-
misation software to the use of day-and-night closed-loop 
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Table 2 Schedule of study visits/phone contacts when the participant is randomised to day-and-night closed -loop combined 
with pump suspend feature (intervention group)
Visit/contact Description
Start relative to previous/next 
visit/activity Duration, hours
Visit 1 Recruitment visit: consent,
HbA1c, screening bloods and 
questionnaires, urine pregnancy test
- 1–4
Training and
run-in
(4 weeks)
Visit 2 Insulin pump training and the initiation 
of study pump, competency assessment
Within 1–3 weeks of visit 1 3–4
Visit 3 CGM training, initiation of CGM, weekly 
contact via phone/email, competency 
assessment
Within 3–7 days of visit 2 2–3
Visit 4* Review pump and CGM data, optimisation 
of treatment, compliance assessment, 
randomisation
After 4 weeks of visit 3 <1
Contact Qualitative interview (with a subset of 
participants/family members)
After randomisation but before 
visit 5
<1
CL + LGS
intervention
(3 months)
Visit 5 CL initiation at clinic/home: urine 
pregnancy test, CL and suspend feature 
training, competency assessment, HbA1c
Within 1 week of visit 4 2–6
Visit 6* Review use of study devices After 24–48 hours of visit 5 <1
Visit 7† Review use of study devices After 1 week of visit 5 <1
Visit 8* Review pump and CGM data After 1 week of Visit 7 <1
Visit 9* End of first month: review pump and CGM 
data
After 2 weeks of visit 8 <1
Visit 10* End of second month: review pump and 
CGM data
After 4 weeks of visit 9 <1
Visit 11 End of closed-loop treatment 
arm (3 months): HbA1c, complete 
questionnaires and follow-up qualitative 
interviews
After 4 weeks of visit 10 1–3
*Could be done via phone/e-mail in the UK. Follow-up by phone is mandatory in the USA only.
†Could be done via phone/e-mail in the UK. In-person visit mandatory in USA only.
CGM, continuous glucose monitoring; CL, closed loop; HbA1c, glycated haemoglobin; LGS, low glucose suspend.
combined with pump suspend feature (threshold 
suspend) or to sensor-augmented insulin pump therapy. 
The randomisation will be stratified at each centre by the 
two age groups (equal proportion of youth (6–21 years) 
and adults (22 years and older)) and HbA1c groups (equal 
proportion of below and above 8.5% (69 mmol/mol)).
A subset of participants randomised to closed-loop 
will be invited to take part in an interview study led by 
an independent team of qualitative researchers at the 
University of Edinburgh. Participants will be interviewed 
before and/or at the end of the closed-loop study period.
home treatment period
All participants will be admitted to a clinical facility at 
the start of each treatment period and have blood tests 
performed for HbA1c. Females of child-bearing age will 
have urine pregnancy test on arrival.
day-and-night closed-loop combined with pump suspend 
feature
Participants will be trained on connection and discon-
nection of the closed-loop system and switching between 
closed-loop and usual pump therapy. Participants will be 
instructed on the use of low-glucose suspend function-
ality and settings. During closed-loop period, meal bolus 
will be delivered by the insulin pump based on carbohy-
drate estimation. Specific instructions during closed-loop 
related to exercise management, sick day rules, hypogly-
caemia and hyperglycaemia management and technical 
troubleshooting will also be reviewed with the partic-
ipants by the study team. Competency on the safe and 
effective use of the closed-loop system will be assessed by 
the study team; only those who demonstrate the same will 
be allowed to continue to the home study phase.
sensor-augmented pump (saP) therapy
Participants randomised to SAP therapy will receive 
training on the effective use of real-time CGM for optimis-
ation of insulin therapy. During SAP therapy, participants 
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Table 3 Schedule of study visits/phone contacts when the participant is randomised to sensor-augmented pump
Visit/contact Description
Start relative to previous/
next visit/activity
Duration, 
hours
Visit 1 Recruitment visit: consent
HbA1c, screening bloods and questionnaires, urine 
pregnancy test
– 1–4
Training and 
run-in
(4 weeks)
Visit 2 Insulin pump training and the initiation study pump, 
competency assessment
Within 1–3 weeks of visit 1 3–4
Visit 3 CGM training, initiation of CGM, weekly contact via 
phone/email, competency assessment
Within 3–7 days of visit 2 2–3
Visit 4* Review pump and CGM data, optimisation of 
treatment, compliance assessment, randomisation
After 4 weeks of visit 3 <1
SAP
intervention
(3 months)
Visit 5 SAP initiation at clinic/home: urine pregnancy test, 
SAP training, competency assessment, HbA1c
Within 1 week of visit 4 2–6
Visit 6* Review use of study devices After 24–48 hours of visit 5 <1
Visit 7† Review use of study devices After 1 week of visit 5 <1
Visit 8* Review pump and CGM data After 1 week of visit 7 <1
Visit 9* End of first month: review pump and CGM data After 2 weeks of visit 8 <1
Visit 10* End of second month: review pump and CGM data After 4 weeks of visit 9 <1
Visit 11 End of SAP treatment arm (3 months): HbA1c, 
complete questionnaires
After 4 weeks of visit 10 1–3
*Could be done via phone/e-mail in the UK. Follow-up by phone is mandatory in the USA only.
†Could be done via phone/e-mail in the UK. In-person visit mandatory in the USA only.
CGM, continuous glucose monitoring; SAP, sensor-augmented pump; HbA1c, glycated haemoglobin.
Figure 2 Closed-loop system prototype. (A) Components 
of the FlorenceM closed-loop system consist of a continuous 
glucose monitoring (CGM) transmitter with Enlite 3 sensor, an 
insulin pump (modified 640G pump) integrated with the CGM 
receiver and a mobile phone running the control algorithm. 
(B) A photo of a participant (obtained with consent) using the 
closed-loop system.
will enter information related to carbohydrate content of 
the meals and premeal capillary glucose values into the 
bolus wizard of the insulin pump. Participants will be 
instructed not to activate threshold suspend (low-glucose 
or predictive low-glucose suspend features). Hypogly-
caemia and hyperglycaemia alarms can be activated and 
personalised as per participants’ requirements.
contact during 3-month home study period
Participants will have identical planned contact visits with 
the study team during the two study periods. The first 
planned contact will occur 24–48 hours once study period 
has begun. During the first 2 weeks of the study period, 
participants will be contacted weekly. Thereafter, partici-
pants will be contacted monthly. Participants will be free 
to optimise their treatment independently.
devices download
Participants will be instructed to download insulin 
delivery and glucose data weekly from the insulin pump 
and blood glucose metre using the Medtronic Carelink 
Clinical download facility.
closed-loop system and low glucose suspend feature
The FlorenceM closed-loop system (figure 2, University of 
Cambridge, Cambridge, UK) comprises a model predic-
tive control algorithm residing on an Android smartphone 
that communicates wirelessly with the insulin pump using 
a proprietary enclosure.
Every 10 min, the system calculates a new temporary 
basal insulin infusion rate, which is automatically sent to 
the study insulin pump. Calculations use a compartment 
model of glucose kinetics describing the effect of rapid-
acting insulin analogues and the carbohydrate content of 
meals on glucose levels.20 The control algorithm will be 
initialised using preprogrammed basal insulin delivery 
downloaded from the study pump. In addition, informa-
tion about participants’ weight and total daily insulin dose 
will be entered at setup. During closed-loop operation, 
the algorithm adapts itself to a particular participant. The 
treat-to-target control algorithm aims to achieve a default 
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glucose level of around 5.8 mmol/L and adjusts the actual 
level depending on fasting versus postprandial status and 
the accuracy of model-based glucose predictions. Sensor 
glucose, insulin delivery, carbohydrate content and other 
information can be visualised by the participants on the 
smartphone device.
No remote monitoring is instigated. For data collection 
purposes, the control algorithm device uploads data on 
a server when the system is charging and connected to 
Wi-Fi.
The pump comprises a CGM receiver and provides 
hypoglycaemia and hyperglycaemia alarms. Hypogly-
caemia and hyperglycaemia alarms can be activated and 
personalised as per participants’ requirements. The 
insulin pump provides standard insulin pump alarms, 
and the smartphone alerts the user about aspects related 
to closed-loop operations (closed-loop started, stopped or 
terminated).
safety precautions during closed-loop
Participants will be trained to perform calibration checks 
before breakfast and evening meals. If sensor glucose is 
above finger-stick glucose by more than 3.0 mmol/L, the 
glucose sensor will be recalibrated. These instructions 
resulted from an in-silico simulation of hypoglycaemia 
and hyperglycaemia risk using the validated Cambridge 
simulator.21
If sensor glucose becomes unavailable, preprogrammed 
insulin delivery will be automatically started within 30 min. 
This limits the risk of insulin underdelivery and overde-
livery. Safety rules limit maximum insulin infusion and 
suspend insulin delivery at sensor glucose at or less than 
4.3 mmol/L or when sensor glucose is rapidly decreasing.
In the event of closed-loop becoming unavailable due 
to loss of sensor glucose input or other system failures, 
insulin delivery will be suspended by the low glucose 
suspend feature set on the insulin pump, provided sensor 
glucose is available. Resumption of insulin delivery will be 
in accordance of the low glucose suspend feature imple-
mented on 640G pump.
Participant withdrawal criteria
The following prerandomisation withdrawal criteria will 
apply:
1. Participant is unable to demonstrate safe use of study 
insulin pump and/or CGM during run-in period as 
judged by the investigator
2. Participant fails to demonstrate compliance with study 
insulin pump and/or CGM during run-in period.
The following prerandomisation and postrandomisation 
withdrawal criteria will apply:
1. Participants may terminate participation in the study 
at any time without necessarily giving a reason and 
without any personal disadvantage
2. Significant protocol violation or non-compliance
3. Any severe hypoglycaemia event related to use of the 
closed-loop system
4. Three severe hypoglycaemia events unrelated to the 
use of the closed-loop system
5. Diabetic ketoacidosis (DKA) unrelated to infusion 
site failure and related to the use of the closed-loop 
system
6. Decision by the investigator or the sponsor that 
termination is in the participant’s best medical 
interest
7. Participant becomes pregnant during the study 
period
8. Allergic reaction to insulin
9. Allergic reaction to adhesive surface of infusion set 
or CGM sensor
10. If patient continues to use pump suspend feature in 
the control group despite advice to the contrary.
Withdrawn participants due to reasons 4–12 will be invited 
to provide blood sample at the end of the planned study 
intervention for the assessment of HbA1c.
Psychosocial methods
A mixed-methods psycho-social evaluation using in-depth 
interviews and validated questionnaires will be conducted 
to determine the utility of the device in terms of accept-
ability of intervention, quality of life, participants’ 
perception of impact on lifestyle and diabetes self-man-
agement.
Participants will be invited to complete the PedsQoL 
questionnaire at screening and at the end of the study 
intervention. In addition, a feedback questionnaire on 
closed-loop-specific experience will be distributed to 
participants/guardians who had been randomised to the 
closed-loop intervention arm.
A subset of participants (individuals aged 16+ years, 
individuals aged 13–15 years and their parent/guard-
ian(s), parent/guardian(s) of participants aged 12 years 
and under) will be invited to take part in an interview 
at baseline (postrandomisation) to enable their histor-
ical diabetes management practices, everyday work/
school and family lives and their initial understandings 
and expectations of using closed-loop technology to be 
captured and explored in depth. The same participants 
will be followed-up at the end of the study intervention 
to determine whether the use of the closed loop-matched 
expectations, whether any difficulties occurred, the bene-
fits and downsides of using closed loop to support diabetes 
self-management for the duration of the trial and their 
views about how the technology might be improved.
A subset of partners/family members will be inter-
viewed at 3 months to capture the benefits of using a 
closed-loop system from their perspectives, how this tech-
nology has impacted on their own lives and on their role 
in supporting diabetes management practices.
Recruitment to the interview study will continue until 
data saturation is achieved; that is, until no new findings 
are identified in new data collected. It is estimated that 
around 20–25 adults and youths with diabetes and 20 
members will be interviewed. If necessary, participants 
will be purposely sampled to allow for diversity in the 
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final sample in terms of age, gender, occupation/educa-
tion and geographical location. Interviews will be digitally 
recorded with consent.
hba1c samples
Blood samples for the measurement of HbA1c levels will 
be taken at three different time points. At screening, 
HbA1c will be measured locally. HbA1c at the beginning 
and end of study intervention will be taken and measured 
at a central laboratory (University of Minnesota, Minne-
apolis, USA) using an International Federation of Clinical 
Chemistry and Laboratory Medicine aligned method.
statistical analysis
All analysis will be conducted on an intention-to-treat 
basis. Data from all randomised participants with or 
without protocol violation including dropouts and with-
drawals will be included in the analysis. Data will not be 
truncated due to protocol deviations.
Primary endpoint
The primary analysis will evaluate between group differ-
ence in the time (midnight to midnight) spent in the target 
glucose range from 3.9 to 10.0 mmol/L (70–180 mg/dL) 
based on sensor glucose levels during the 12-week free-
living phase.
A 5% significance level will be used to declare statistical 
significance for the primary outcome comparison.
Mean (SD) for % time spent in the target range will be 
tabulated by treatment group. A linear model will be used 
to compare the difference between the two intervention 
arms, while adjusting for baseline % time spent in the 
target glucose range and random site effect. A 95% CI 
will be reported for the difference between the treatment 
groups based on the linear model. Normality of the resid-
uals will be assessed. If the residuals have highly skewed 
distribution, then ranked normal score transformation 
of outcome data will be applied in the regression model. 
However, previous experience suggests that % time in 
target glucose range will follow an approximately normal 
distribution. A detailed analysis plan will be provided 
separately.
Secondary endpoints
The following outcomes on the two treatment arms will 
be compared:
 ► HbA1c at 12 weeks
 ► Time spent below target glucose (3.9 mmol/L) 
(70 mg/dL)
 ► Time spent above target glucose (10.0 mmol/L) 
(180 mg/dL)
 ► Average, SD and coefficient of variation of glucose 
levels
 ► Time with glucose levels <3.5 mmol/L (63 mg/dL) 
and <2.8 mmol/L (50 mg/dL)
 ► Time with glucose levels in the significant 
hyperglycaemia (glucose levels >16.7 mmol/L) 
(300 mg/dL)
 ► Total, basal and bolus insulin dose (units/kg of body 
weight)
 ► Area under the curve of glucose below 3.5 mmol/L 
(63 mg/dL)
 ► Number of pump suspend events (applicable to 
intervention arm)
 ► Change in body weight from screening to end of study.
Glycaemic metrics will be based on sensor glucose 
levels collected during the 12-week intervention period. 
Similar linear models as the primary outcome will be 
used to compare the between-treatment difference. 
For those metrics that have highly skewed distribution, 
a ranked normal score transformation of outcome data 
will be applied in the regression model. p Value <0.05 will 
be used to declare statistical significance for selected 
secondary outcomes (HbA1c, glucose CV, % time below 
3.9 mmol/L, % time above 10.0 mmol/L, total daily 
insulin and change in body weight). For other outcomes, 
to reduce the inflation of type I error caused by multiple 
comparisons, p value <0.01 will be used to define statis-
tical significance.
A subset of sensor glucose and insulin metrics will also 
be tabulated separately for daytime period (08:00–00:00) 
and night-time period (00:00–08:00).
 ► Percent time with glucose in target range of 3.9–
10.0 mmol/L (70–180 mg/dL)
 ► Mean glucose
 ► Glucose variability as measured by SD
 ► Percent time with glucose level <3.5 mmol/L (63 mg/
dL)
 ► Amount of delivered insulin.
Trends in sensor glucose data collected within interven-
tion arms will be evaluated on a 4-weekly basis.
safety analysis
The following safety outcomes will be tabulated by treat-
ment group:
 ► Number of subjects with any DKA events
 ► Number of episodes of DKA events per subject and 
incidence rate per 100 person-years
 ► Number of subjects with any severe hypoglycaemia 
events
 ► Number of episodes of severe hypoglycaemia events 
per subject and incidence rate per 100 person-years
 ► Number of subjects with any severe 
hyperglycaemia events as defined by fingerprick 
glucose >16.7 mmol/L (>300 mg/dL) and plasma 
ketones >0.6 mmol/L
 ► Number of episodes of severe hyperglycaemia events 
per subject and incidence rate per 100-person years.
Above safety data will be tabulated for all subjects in the 
two intervention periods, including dropouts and with-
drawals, irrespective of whether sensor glucose data are 
available and irrespective of whether closed loop was 
operational. All adverse events will be listed for the entire 
study duration.
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If there are enough observed events to allow formal 
statistical modelling for above safety outcomes, the 
following analyses will be conducted. The event rates will 
be compared using a Poisson regression model adjusting 
for random site effect. If outliers exist, a robust Poisson 
regression model will be used instead. Binary variables will 
be compared using a logistic regression model adjusting 
for random site effect. Models involving severe hypogly-
caemia events will also adjust for severe hypoglycaemia in 
the previous 6 months before enrolment.
utility evaluation
The amount of CGM use will be calculated for both inter-
vention arms, and the amount of closed-loop system used 
will be calculated for the closed-loop treatment arm only 
over the 12-week intervention and by 4-weekly period. 
The difference in CGM use between treatment groups 
will be compared using similar linear model as described 
for primary outcome.
subgroup analysis
No subgroups were considered during the power calcu-
lations. Interpretation of any subgroup analyses will 
depend on whether the overall analysis demonstrates a 
significant treatment group difference. In the absence of 
such an overall difference and if performed, the following 
subgroup analyses will be interpreted with caution: (1) 
age (6–12 years, 13–21 years, 22 years and older), (2) 
gender, (3) race–ethnicity, (4) clinical centre and (5) 
baseline HbA1c (<8.5% and ≥8.5%).
Psychosocial evaluation
Questionnaires for diabetes-related quality-of-life assess-
ment (PedsQL v3.2) will be collected at screening and at 
the end of the study intervention. For subjects ≥18 years 
of age, only answers from the participants themselves will 
be collected; for subject s≤17 years of age, answers will be 
collected from both parent version and child version.
At each assessment time point, mean±SD score for 
each dimension and the total score will be tabulated by 
intervention arm for both parent version and participant 
version. The between-group difference of each score at 
end of study will be assessed using a similar linear model 
as described previously by adjusting for corresponding 
score at baseline.
Interview data will be analysed thematically and longi-
tudinally using the method of constant comparison.22 
To maximise rigour, at least two experienced qualitative 
researchers will be involved in the analysis. NVivo9, a 
qualitative software package, will be used to facilitate data 
coding/retrieval.
Per-protocol analysis
Per-protocol analysis will be conducted to compare 
the primary endpoint limited to participants who used 
closed loop for at least 80% of the of the 3-month study 
period (with CGM data are available for at least 50% of 
the study period). In the SAP group, per-protocol analysis 
will be conducted on those whose CGM data are available 
for at least 50% of study period.
Interim analysis
No interim analysis will be performed.
Power calculation
On the basis of our previous day-and-night closed-loop 
studies10 23 and a conservative estimate of 10%points 
improvement in time when glucose is in target glucose 
range with an SD of 14.5% points, 76 subjects are 
required to achieve 85% power and an alpha level of 0.05 
(two tailed). A total of 84 are planned to be randomised 
to allow for dropouts. It is expected that 95 or more 
subjects will be recruited; recruitment will continue 
until it is anticipated that a sufficient number have been 
enrolled to meet the randomisation goal. Randomisation 
target may be exceeded since all of the subjects who have 
initiated the run-in phase will be permitted to continue 
into the intervention.
study ManageMent
data safety Monitoring Board
An independent Data Safety Monitoring Board (DSMB) 
will comprise a chairperson and two experts. DSMB will 
be informed of all serious adverse events  and any unantic-
ipated device effects/events that occur during the study. 
DSMB will review compiled adverse event data and peri-
odic intervals. DSMB will report to the study management 
committee any safety concerns and recommendations 
for suspension or early termination of the investigation. 
Composition of DSMB is shown in online supplementary 
appendix file 1 .
study sponsors
In the UK, the study sponsor is the Cambridge University 
Hospitals NHS Foundation Trust, jointly with the Univer-
sity of Cambridge. Study sponsor in the USA is the Jaeb 
Center for Health Research.
study management committee
The study management committee consisting of the chief 
investigator, study coordinators and study data manager 
will confer at least quarterly to discuss the operational 
aspects of the study. The principal clinical investigators 
may also participate. Composition of the study manage-
ment committee is shown in online supplementary 
appendix.
study monitoring
The study coordinators will ensure that the study is 
conducted in accordance with Good Clinical Practice 
standards through site monitoring visits. A monitoring 
plan will be written and agreed prior to randomisation.
data management
Confidentiality of participant data shall be observed at all 
times during the study. Personal details for each partici-
pant taking part in the research study and linking them 
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to a unique identification number will be held locally on 
a study screen log in the Trial Master File at each of the 
investigation centres. These details will not be revealed 
at any other stage during the study, and all results will 
remain anonymous. Study identification number and 
bar codes will be used on the electronic case report forms 
and all the blood samples that are collected throughout 
the study.
Electronic data will be stored on password-protected 
computers. All paper records will be kept in locked 
filing cabinets, in a secure office at each of the investi-
gation centres. Only members of the research team and 
collaborating institutions will have password access to 
the anonymised electronic data. Only members of the 
research teams will have access to the filing cabinet. Paper 
copies of the data will be stored for 15 years.
Direct access to the source data will be provided for 
monitoring, audits, research ethics committee (REC)/
institutional review board (IRB) review and regulatory 
authority inspections during and after the study. The fully 
anonymised data may be shared with third parties (EU or 
non-EU based) for the purposes of advancing manage-
ment and treatment of diabetes.
Indemnity
Indemnity for any harm rising on the conduct of research 
will be provided according to local arrangements in 
respective countries.
1. UK: any liability arising from study design will be 
covered by the clinical trial insurance policy organised 
by the University of Cambridge. National Health 
Service indemnity cover will apply for any claims 
arising from management and conduct of research.
2. USA: any liability arising from study design will be 
under the responsibility of the participants or their 
insurance company.
ethIcs and dIsseMInatIon
The study has received approval from independent REC 
and IRB in the UK and the USA. The study has undergone 
a review by regulatory authorities in the UK (Medicines 
and Healthcare products Regulatory Agency) and in the 
USA (FDA). All participants will be provided with oral 
and written information about the trial and procedures 
involved in the study before obtaining written informed 
consent.
Study operating procedures for monitoring and 
reporting of all adverse events and adverse device effects 
will be in place including serious adverse events, serious 
adverse device effects and specific adverse events such 
as severe hypoglycaemia and significant hyperglycaemia 
with ketosis. DSMB will be informed of all serious adverse 
events and any unanticipated adverse device/method 
effects that occur during the study and will review 
compiled adverse events data at periodic intervals.
Any substantial amendments to the protocol and 
other documents shall be notified to, and approved by, 
the independent REC and IRB (UK, Cambridge East 
Research Ethics Committee (#15/EE/0324); USA, Jaeb 
Center for Health Research Institutional Review Board 
certified by the Office for Human Research Protections 
(FWA #00000024)) and the regulatory authorities, prior 
to implementation as per nationally agreed guidelines.
Screening and recruitment commenced in June 2016, 
and the study is expected to be completed by the end of 
2017. The study results will be disseminated by peer-re-
viewed publications and conference presentations.
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